Online citations, reference lists, and bibliographies.
← Back to Search

The Use Of Cyclosporine In Dermatology: Part II.

C. Ryan, Karrie T Amor, A. Menter
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
UNLABELLED Cyclosporine is highly effective in the treatment of a multitude of dermatoses. Concern over its side effect profile has limited its use in dermatology. Adverse effects are, for the most part, dose dependent and related to duration of therapy. Using the recommended monitoring protocols results in a significant decrease in the incidence of cyclosporine-related toxicities. This article provides a comprehensive review of the pharmacokinetics of cyclosporine, potential drug interactions, adverse effects, and recommendations for monitoring in patients treated with cyclosporine. The use of cyclosporine in pregnancy and in the pediatric population is also addressed. LEARNING OBJECTIVES After completing this learning activity, participants should be familiar with the monitoring guidelines of cyclosporine, its contraindications, its possible drug interactions, its adverse effect profile, and its use in pregnancy and the childhood and adolescent populations.
This paper references
10.1016/S0140-6736(65)92676-0
HYPERBARIC OXYGENATION CHRONIC OSTEOMYELITIS.
W. Slack (1965)
10.1002/j.1552-4604.1990.tb01868.x
Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration
S. Gupta (1990)
10.1111/j.1365-2133.1995.tb08633.x
Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy
H. Granlund (1995)
10.1159/000248778
Ciclosporin A in acrodermatitis continua.
H. Zachariae (1987)
10.1097/00008571-200403000-00002
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
V. Haufroid (2004)
10.1111/j.1365-2133.1990.tb02880.x
Efficacy of low‐dose cyclosporin A in psoriasis: results of dose‐finding studies
P. Timonen (1990)
10.1016/S0190-9622(97)70296-2
Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine.
N. Mobini (1997)
Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides.
N. Serkova (2003)
10.1111/j.1365-2133.1990.tb07288.x
Renal function after long‐term low‐dose cyclosporin for psoriasis
A. Powles (1990)
Histopathology of cyclosporine nephrotoxicity.
M. Mihatsch (1988)
10.1046/j.1468-3083.2002.00459.x
Schnitzler's syndrome with monoclonal IgGκ gammopathy: good response to cyclosporin
M. Pascual-López (2002)
10.1080/09546630410033006
Topical tretinoin or adapalene in acne vulgaris: an overview
S. Jain (2004)
10.1016/S0190-9622(97)80219-8
Cyclosporine as maintenance therapy in patients with severe psoriasis.
J. Shupack (1997)
10.1006/JSRE.2001.6233
Cyclosporine directly causes oxidative stress and promotes Epstein-Barr virus transformation of human B cells.
C. Chen (2001)
10.1159/000066425
Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis
D. Thaçi (2002)
Absence of genotoxic potential for cyclosporine in experimental systems.
T. Zwanenburg (1988)
10.1056/NEJM199206183262502
Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.
G. Feutren (1992)
10.1136/adc.76.2.159
Atopic eczema: its impact on the family and financial cost
J. C. Su (1997)
10.1097/00007890-199801270-00019
Breast-feeding during treatment with cyclosporine.
G. Nyberg (1998)
10.1097/01.TP.0000130981.55654.78
MDR-1 C3435T Polymorphism Influences Cyclosporine A Dose Requirement in Liver-Transplant Recipients
L. Bonhomme-Faivre (2004)
10.1007/s10067-005-0070-8
CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases
I. Koetter (2005)
Effect of isradipine on cyclosporin A-related hypertension.
M. A. van den Dorpel (1994)
10.1034/J.1398-9995.2002.23685.X
Urticaria and cyclosporine.
P. G. Bonilla (2002)
10.1016/0190-9622(92)70117-X
The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine.
J. Koo (1992)
10.1097/01.TP.0000057241.69355.59
Cyclosporine-associated hyperkalemia: report of four allogeneic blood stem-cell transplant cases
Y. Caliskan (2003)
10.1136/ard.49.8.603
Cyclosporin A in psoriatic arthritis: an open study.
K. Steinsson (1990)
10.1542/peds.2004-0374
Effects of Atopic Dermatitis on Young American Children and Their Families
S. Chamlin (2004)
10.1345/aph.10228
Rhabdomyolysis and HMG-CoA Reductase Inhibitors
M. A. Omar (2001)
10.1111/j.1610-0387.2008.06745.x
Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series
D. Siepmann (2008)
10.1016/J.JACI.2004.02.049
Chronic urticaria: pathogenesis and treatment.
A. Kaplan (2004)
10.1007/S11926-996-0021-7
Treatment of refractory polymyositis and dermatomyositis
S. Ytterberg (2006)
10.1046/j.1365-2133.2000.03418.x
The Salford Psoriasis Index: an holistic measure of psoriasis severity
B. Kirby (2000)
Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy.
N. Serkova (1999)
Lichen planopilaris and psoriasis.
Tameka K Lane (2008)
The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis.
Mohammad Shaheedi-Dadras (2008)
Behçet's disease with relapsing cutaneous polyarteritis-nodosa-like lesions, responsive to oral cyclosporine therapy.
A. Vikas (2003)
10.2165/00128071-200405030-00007
Eosinophilic Pustular Folliculitis
E. Ellis (2004)
10.1001/ARCHDERM.1993.01680310043006
Cyclosporine in the treatment of palmoplantar pustulosis. A randomized, double-blind, placebo-controlled study.
S. Reitamo (1993)
10.1016/0140-6736(90)90990-M
Cyclosporin monitoring in psoriasis
G. Feutren (1990)
10.1017/S1462399400001769
Molecular targets for existing and novel immunosuppressive drugs.
S. Stepkowski (2000)
10.1046/j.1468-3083.2002.00570_5.x
Cyclosporin A and alopecia areata
J. Moreno (2002)
10.1007/S10165-006-0556-5
A case of dermatomyositis complicated with pneumomediastinum
M. Terao (2007)
10.1111/j.1365-2133.1992.tb14836.x
Severe lichen planus clears with very low‐dose cyclosporin
N. Levell (1992)
10.1097/00007890-200005270-00013
Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients: analysis of lymphocyte subpopulations and immunoglobulin serum levels.
S. di Paolo (2000)
Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy.
C. Salvarani (1992)
10.1046/j.1365-2133.1996.d01-1074.x
Anti‐inflammatory efficacy of low‐dose cyclosporin A in psoriatic arthritis. A prospective multicentre study
G. Mahrle (1996)
10.1097/00007890-198511000-00001
INDIVIDUALIZATION OF CYCLOSPORINE THERAPY USING PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS
B. Kahan (1985)
10.1046/j.1365-2133.1997.d01-1229.x
Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study
J. Berth-Jones (1997)
10.1542/peds.108.3.776
Transfer of drugs and other chemicals into human milk.
R. Roberts (2001)
10.1016/j.jaci.2008.07.006
Treatment of chronic autoimmune urticaria with omalizumab.
A. Kaplan (2008)
10.1046/j.1365-2133.1999.02976.x
Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis
Clark (1999)
10.1111/j.1365-2133.1990.tb02884.x
Renal side‐effects of cyclosporin A
J. Mason (1990)
10.1016/S0041-1345(97)00458-2
Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun.
V. Lamarque (1997)
10.3310/HTA4400
A systematic review of treatments for severe psoriasis.
C. Griffiths (2000)
10.1161/01.HYP.23.6.957
Cyclosporine produces endothelial dysfunction by increased production of superoxide.
D. Diederich (1994)
10.1016/S0149-2918(03)80161-3
A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A
S. Pollard (2003)
10.1016/S0041-1345(99)00085-8
Bioequivalence criteria for cyclosporine.
A. Johnston. (1999)
10.1016/0190-9622(92)70012-5
Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study.
E. Christophers (1992)
10.1111/j.1365-2133.1989.tb07790.x
Long‐term cyclosporin for psoriasis
C. E. Griffiths (1989)
10.1111/j.1365-2133.2007.08283.x
Guidelines for evaluation and management of urticaria in adults and children
C. Grattan (2007)
10.1016/S0190-9622(97)70342-6
Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation.
J. Shapiro (1997)
10.1002/14651858.CD004413.pub2
Interventions for alopecia areata.
F. Delamere (2008)
10.1016/j.jaad.2008.03.023
National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Sean D. Doherty (2008)
10.1016/0264-410X(93)90278-6
Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients.
A. Lefébure (1993)
10.1016/S0140-6736(89)91922-3
GYNAECOLOGISTS' ATTITUDES TO ABORTION
W. Savage (1989)
10.1016/S0190-9622(96)90726-4
Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.
N. Lowe (1996)
10.1046/j.1365-2133.1997.d01-1146.x
Long‐term efficacy and safety of cyclosporin in severe adult atopic dermatitis
J. Berth-Jones (1997)
10.1111/j.1600-0781.1997.tb00109.x
Cyclosporin A therapy for severe solar urticaria
D. W. Edström (1997)
10.1111/j.1365-2133.1990.tb02888.x
Renal side‐effects of cyclosporin A with special reference to autoimmune diseases
M. Mihatsch (1990)
10.1016/J.JAAD.2004.06.043
Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression.
J. Lelièvre (2005)
10.1046/j.1365-2133.1999.02977.x
Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1‐year multicentre, randomized study
Ho (1999)
10.1016/J.JAAD.2003.08.003
Guidelines of care for atopic dermatitis
J. Hanifin (2004)
10.1097/00007890-200104270-00006
Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.
B. Bar Oz (2001)
10.1111/j.1365-2230.2008.02866.x
Pyoderma gangrenosum following pacemaker insertion
A. Duncan (2009)
10.1097/01.ASN.0000139069.59466.D8
Long-term effects of in utero exposure to cyclosporin A on renal function in the rabbit.
A. Tendron-Franzin (2004)
10.1007/BF00857572
Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts
K. Morozumi (2004)
10.1111/j.1365-2133.1989.tb01402.x
Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A
E. Higgins (1989)
10.1080/09546630701846095
Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata
Beom Kyung Kim (2008)
10.1016/S0272-6386(86)80107-X
Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy.
S. Tomlanovich (1986)
10.2340/00015555756569
Remission of ordinary psoriasis following a short clearance course of cyclosporin.
N. Levell (1995)
The risk of malignancy associated with psoriasis.
D. Margolis (2001)
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.
G. Krueger (2001)
10.1001/JAMA.1986.03380220076026
Cyclosporine improves psoriasis in a double-blind study.
C. Ellis (1986)
10.1016/S0190-9622(08)81109-7
Acrodermatitis continua-type of pustular psoriasis responds to low-dose cyclosporine.
R. Peter (1990)
A Randomized Double-blind Placebo-controlled Trial
J. Smith (2004)
10.1097/00007890-200204150-00007
Inhibition of endothelin-1 improves survival and vasculopathy in rat cardiac transplants treated with cyclosporine
M. Simonson (2002)
10.1016/J.JAAD.2006.08.040
Prevalence of cardiovascular risk factors in patients with psoriasis.
A. Neimann (2006)
10.1046/j.1365-2133.2003.05535.x
Guidelines for the management of alopecia areata
S. M. MacDonald Hull (2003)
10.1196/annals.1361.110
Rationale for T Cell Inhibition by Cyclosporin A in Major Autoimmune Diseases
G. Ferraccioli (2005)
10.1097/00007890-199911150-00023
The temporal profile of calcineurin inhibition by cyclosporine in vivo.
P. Halloran (1999)
10.1001/JAMA.296.14.1735
Risk of myocardial infarction in patients with psoriasis.
J. Gelfand (2006)
10.1097/00007890-198608000-00009
INCREASED FACTOR VIII AS AN INDEX OF VASCULAR INJURY IN CYCLOSPORINE NEPHROTOXICITY
Z. Brown (1986)
10.1097/00007890-199401000-00021
ANALYSIS OF PERIPHERAL BLOOD LYMPHOCYTE POPULATIONS AND IMMUNE FUNCTION FROM CHILDREN EXPOSED TO CYCLOSPORINE OR TO AZATHIOPRINE IN UTERO
L. Pilarski (1994)
10.1111/j.1524-4725.2009.01109.x
Intractable wounds caused by pyoderma gangrenosum in a patient with critical limb ischemia treated with cyclosporine and adjuvant sympathectomy.
Y. Takahashi (2009)
10.1111/j.1365-2133.1993.tb15145.x
Renal function and biopsy findings after 5 years' treatment with low‐dose cyclosporin for psoriasis
A. Powles (1993)
10.1016/S0140-6736(95)91618-0
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation
T. Stewart (1995)
10.1046/j.1365-2133.2000.03241.x
Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy
J. Harper (2000)
10.1016/0190-9622(90)70015-A
Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study.
V. Ho (1990)
Treatment of idiopathic nephrotic syndrome with cyclosporin A in children.
P. Niaudet (1991)
10.1111/j.1365-2133.1990.tb08255.x
Cyclosporin A for treatment of severe lichen planus
P. Pigatto (1990)
10.1046/j.1365-2133.2001.04183.x
Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin
C. R. Touw (2001)
10.1111/j.1365-2133.1994.tb06886.x
Cyclosporin A in the treatment of chronic dermatitis of the hands
S. Reitamo (1994)
10.1016/j.jaci.2008.10.050
What the first 10,000 patients with chronic urticaria have taught me: a personal journey.
A. Kaplan (2009)
10.1111/j.1468-3083.2008.02987.x
A non‐responsive chronic autoimmune urticaria in a 12‐year‐old autistic girl treated with cyclosporin
K. Giuliodori (2009)
10.2165/00128071-200102010-00007
Cyclosporine in Severe Psoriasis
L. Faerber (2001)
10.1016/S0140-6736(76)91644-5
PRENATAL PREDICTION OF MYOTONIC DYSTROPHY
J. Insley (1976)
Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients.
J. Curtis (1993)
10.1056/NEJM199101313240501
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.
C. Ellis (1991)
10.1001/ARCHDERM.1989.01670160055007
Cyclosporine in the treatment of psoriatic arthritis.
A. Gupta (1989)
10.1056/NEJME058018
Immunosuppressive drugs and the risk of cancer after organ transplantation.
J. Dantal (2005)
10.1007/BF00193480
Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children
E. Jacqz-Aigrain (2004)
Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.
A. Spadaro (1995)
10.1016/J.JAAD.2006.04.078
Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.
G. Vena (2006)
10.1016/0190-9622(90)70032-D
Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis.
A. Gupta (1990)
10.1016/0190-9622(95)91286-X
Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.
S. Gottlieb (1995)
10.1016/j.jaut.2009.02.011
Behçet's disease--a contemporary review.
D. Mendes (2009)
10.1111/j.1610-0387.2008.06834.x
Systemic therapeutic options for severe atopic dermatitis
C. Bussmann (2009)
10.1093/CLINIDS/22.2.295
The immunogenicity of influenza virus vaccine in solid organ transplant recipients.
E. Blumberg (1996)
10.1161/01.HYP.25.1.77
Hypertension after renal transplantation. Calcium channel or converting enzyme blockade?
M. R. van der Schaaf (1995)
10.1111/j.1468-3083.2006.01877.x
Efficacy and safety of long‐term treatment with cyclosporin A for atopic dermatitis
D. Hijnen (2007)
10.1016/j.jaad.2007.08.016
Infantile pyoderma gangrenosum.
Maeve A. McAleer (2008)
10.1111/j.1365-2133.1985.tb02285.x
Isolation, barrier properties and lipid analysis of stratum compactum, a discrete region of the stratum corneum
P. A. Bowser (1985)
10.1007/s002770000262
"Pseudotumor cerebri" following allogeneic bone marrow transplantation (BMT)
M. González Vicent (2001)
10.2340/00015555-0033
Adult T-cell lymphoma/leukaemia developing in a patient with psoriasis treated with long-term cyclosporine.
H. Watabe (2006)
10.1034/J.1600-051X.2000.027004217.X
Risk factors for drug-induced gingival overgrowth.
R. Seymour (2000)
10.2165/00128071-200708020-00004
Efficacy and Safety of Cyclophosphamide, Azathioprine, and Cyclosporine (Ciclosporin) as Adjuvant Drugs in Pemphigus Vulgaris
M. Olszewska (2007)
Enhancement of cyclosporin nephrotoxicity by diuretic therapy.
G. Deray (1989)
10.1586/erp.09.23
Burden of skin diseases
M. K. Basra (2009)
10.1136/ard.2008.096677
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
O. Kowal-Bielecka (2009)
10.1080/0891693031000067296
Immunosuppressive Drug Use in Pregnancy
M. Petri (2003)
10.1016/S0140-6736(95)92780-8
Risk of neoplasia in renal transplant patients
N. London (1995)
10.1177/106002809603000734
Elevated Blood Concentrations of Cyclosporine and Kidney Failure after Bezafibrate in Renal Graft Recipient
M. Hirai (1996)
10.1111/J.1365-2133.1993.TB03532.X
Cyclosporin A in severe, therapy‐resistant atopic dermatitis: report of an international workshop, April 1993
R. Camp (1993)
10.1046/j.1468-3083.2001.00174-2.x
Epidermolysis bullosa acquisita responsive to cyclosporin therapy
M. L. Khatri (2001)
10.1111/j.1468-3083.2007.02325.x
Relapsing lichen actinicus successfully treated with cyclosporin
L. Gallo (2008)
Cyclosporin A responsive chronic severe vesicular hand eczema.
C. Petersen (1992)
10.1097/00007890-199811270-00014
Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation.
T. Dengler (1998)
10.1159/000249288
Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients.
P. Bencini (1986)
10.1016/S0190-9622(96)90285-6
Treatment of pyoderma gangrenosum.
R. Chow (1996)
10.1016/S0140-6736(77)91391-5
AMIKACIN RESISTANCE DEVELOPING IN PATIENT WITH PSEUDOMONAS ÆRUGINOSA BRONCHOPNEUMONIA
I. Amirak (1977)
10.1016/0140-6736(91)90134-B
Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
J. Sowden (1991)
10.1111/j.1346-8138.2008.00466.x
Low‐dose and short‐term cyclosporine treatment in patients with chronic idiopathic urticaria: A clinical and immunological evaluation
H. Serhat Inaloz (2008)
10.1111/j.1525-1470.2005.22403.x
Oral Lichen Planus in Childhood
R. Laeijendecker (2005)
10.1159/000018397
Three Cases of Pityriasis rubra pilaris Successfully Treated with Cyclosporin A
K. Usuki (2000)
10.1016/0190-9622(92)70025-B
Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day.
D. Margolis (1992)
10.1016/J.TRANSPROCEED.2004.01.012
Renal outcome of children exposed to cyclosporine in utero.
P. Cochat (2004)
10.3109/03009749709065660
Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?
K. Maeda (1997)
10.1157/13101341
Partial response to cyclosporine in a patient with Schnitzler's syndrome.
J. Carbone (2007)
10.1111/j.1468-3083.2006.02084.x
Palmoplantar lichen planus with umbilicated papules: an atypical case with rapid therapeutic response to cyclosporin
G. Karakatsanis (2007)
10.1016/S0041-1345(98)01519-X
Developmental well-being in offspring of women receiving cyclosporine post-renal transplant.
C. Stanley (1999)
10.1046/J.1365-4362.2000.00863.X
Corticosteroid-resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy.
T. Demitsu (2000)
10.3109/08037059209065124
Raised plasma concentrations of endothelin-1 and -3 in marmosets with acute aortic stenosis: no relation to the renin-angiotensin system.
D. Gustafsson (1992)
10.1111/J.1600-051X.1991.TB01698.X
The effect of a plaque control programme on the incidence and severity of cyclosporin-induced gingival changes.
R. Seymour (1991)
10.1016/0300-483X(92)90166-C
The carcinogenicity of ciclosporin.
B. Ryffel (1992)
10.1046/j.1468-3083.2001.00221.x
One‐year treatment of chronic urticaria with mizolastine: efficacy and safety. J Eur Acad Dermatol Venereol 2000; 14: 83–90
W. Aberer (2001)
The activity of the Liver Transplant Center of Milan, Italy.
L. Fassati (1988)
10.1097/01.tp.0000264197.88129.2e
Polymorphisms of Multidrug Resistance Gene (MDR1) and Cyclosporine Absorption in De Novo Renal Transplant Patients
C. J. Foote (2007)
10.1097/01.rhu.0000249894.03016.de
Behçet Disease: Recommendation for Clinical Management of Mucocutaneous Lesions
Pin Lin (2006)
10.1016/j.jaad.2008.02.043
The treatment and prognosis of dermatomyositis: an updated review.
Luciano J. Iorizzo (2008)
10.1159/000069946
Primary Cutaneous CD30+ Large T-Cell Lymphoma in a Patient with Psoriasis Treated with Cyclosporine
M. Corazza (2003)
10.1111/1523-1747.EP12876222
Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis.
K. Cooper (1990)
10.1111/1523-1747.EP12468979
Cyclosporin A prolongs human hair growth in vitro.
M. Taylor (1993)
10.1016/S0140-6736(01)06179-7
Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study
I. Marcil (2001)
10.1038/KI.1994.387
A prospective study of renal structure and function in psoriasis patients treated with cyclosporin.
E. Young (1994)
10.1046/j.1365-2133.1998.02555.x
Double‐blind placebo‐controlled study of long‐term low‐dose cyclosporin in the treatment of palmoplantar pustulosis
Erkko (1998)
10.1016/J.TRANSPROCEED.2005.02.098
Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity.
J. Yuan (2005)
Surgery and cyclosporine A in the treatment of erosive lichen planus of the feet.
P. Patrone (1998)
10.1111/j.1468-3083.2007.02226.x
Intermittent vs. continuous 1‐year cyclosporin use in chronic plaque psoriasis
G. Chaidemenos (2007)
10.1016/J.JAAD.2004.07.043
Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature.
C. Dadlani (2005)
10.1067/MJD.2000.103815
A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life.
W. Czech (2000)
10.1016/S0190-9622(97)80354-4
Efficacy of cyclosporine on mucocutaneous manifestations of Behçet's disease.
O. Avcı (1997)
10.1016/S0896-8411(89)80010-1
The risk of neoplasms in patients treated with cyclosporine A.
I. Cockburn (1989)
10.1046/J.1523-1747.2003.12040.X
Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
C. Paul (2003)
10.1001/JAMA.1989.03430010065032
Effects of cyclosporine therapy on plasma lipoprotein levels.
C. Ballantyne (1989)
10.1111/j.1365-2133.1990.tb07290.x
Cyclosporin A treatment of systemic sclerosis
H. Zachariae (1990)
10.1111/j.1365-4632.2004.02245.x
Cyclosporine controls epidermolysis bullosa acquisita co‐occurring with acquired factor VIII deficiency
J. Maize (2005)
10.1046/j.1365-2133.2003.05384.x
CD30+ T‐cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab
E. Mahé (2003)
10.1016/S0190-9622(98)70325-1
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
M. Lebwohl (1998)
10.1159/000246070
Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
A. Kuijpers (1997)
Comparative effects of enalapril and nifedipine on renal hemodynamics in hypertensive renal allograft recipients.
S. Abu-Romeh (1992)
10.1159/000051694
Cyclosporin for Atopic Dermatitis in Children
J. Harper (2001)
10.1016/j.jaad.2009.05.048
Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.
M. Rosenbach (2010)
10.1016/0190-9622(93)70067-4
An approach to the treatment of moderate to severe psoriasis with rotational therapy.
G. Weinstein (1993)
10.1093/RHEUMATOLOGY/39.8.865
Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma.
S. Morton (2000)
10.1111/J.1087-0024.2004.09115.X
The burden of psoriasis is not determined by disease severity only.
V. M. Heydendael (2004)
10.1002/j.1875-9114.1993.tb02767.x
Bioequivalence of Soft Gelatin Capsules and Oral Solution of a New Cyclosporine Formulation
J. Kovarik (1993)
10.1038/SJ.JID.5700410
The risk of lymphoma in patients with psoriasis.
J. Gelfand (2006)
10.1067/S0190-9622(03)00873-9
Short course of oral cyclosporine in lichen planopilaris.
P. Mirmirani (2003)
10.1111/j.1468-3083.1998.tb00976.x
The efficacy, tolerability and safety of a new oral formulation of Sandimmun®‐Sandimmun Neoral® in severe refractory atopic dermatitis
N. Atakan (1998)
10.1111/j.1346-8138.2007.00305.x
Efficacy and safety of preprandial versus postprandial administration of low‐dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris
H. Hashizume (2007)
10.1111/j.1365-2133.1990.tb02883.x
Renal function and blood pressure in psoriatic patients treated with cyclosporin A
G. Feutren (1990)
10.1111/j.1365-2133.1996.tb00704.x
The long‐term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens
I. Zonneveld (1996)
10.2340/0001555576442443
Plasma endothelin in psoriasis: possible relations to therapy and toxicity.
H. Zachariae (1996)
10.1016/S0140-6736(89)92381-7
DOUBLE-MASKED TRIAL OF CYCLOSPORIN VERSUS COLCHICINE AND LONG-TERM OPEN STUDY OF CYCLOSPORIN IN BEHÇET'S DISEASE
K. Masuda (1989)
10.1016/j.transproceed.2007.11.040
Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients.
G. Bozkaya (2008)
Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome.
G. Feutren (1990)
10.1111/j.1440-0960.2005.00187.x
Prurigo nodularis: A review
M. R. Lee (2005)
10.1016/S0272-6386(12)80374-X
Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine.
Y. Pei (1994)
10.1111/j.1365-2133.1993.tb03170.x
Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double‐blind, placebo‐controlled trial
M. Salek (1993)
10.1111/j.1468-3083.2006.02023.x
Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta‐analysis
J. Schmitt (2007)
10.1016/J.TRANSPROCEED.2005.01.077
GENETIC POLYMORPHISMS OF CYP3A5 GENES AND CONCENTRATION OF THE CYCLOSPORINE AND TACROLIMUS
Y. Zhao (2005)
10.1111/j.1365-2133.1990.tb02882.x
Side‐effect profile of cyclosporin A in patients treated for psoriasis
P. Krupp (1990)
10.2165/00003495-200161130-00006
Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
C. Dunn (2001)
10.1111/j.1365-2133.2003.05665.x
Guidelines for the management of pemphigus vulgaris
K. Harman (2003)
10.1111/j.1749-6632.2009.04744.x
Rituximab in Severe Pemphigus
E. Schmidt (2009)
10.1046/J.1523-1755.1999.00481.X
Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells.
P. Avdonin (1999)
Combination of cyclosporine A and topical corticosteroid in the treatment of psoriasis.
C. E. Griffiths (1988)
10.1080/08916930500124023
Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants
K. Takada (2005)
10.1016/j.jaad.2008.02.040
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
A. Gottlieb (2008)
10.1046/j.1365-2133.1998.02122.x
Renal function after 10 years' treatment with cyclosporin for psoriasis
Powles (1998)
10.1111/j.1468-3083.2004.01057.x
Prophylactic short‐term use of cyclosporin in refractory polymorphic light eruption
O. Lasa (2004)
10.1016/S0190-9622(88)70132-2
Treatment of nine cases of pemphigus vulgaris with cyclosporine.
H. Barthélémy (1988)
10.1046/J.1523-1755.1998.00014.X
Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension.
N. Vaziri (1998)
10.1097/00007890-198803000-00029
Effect of obesity on cyclosporine disposition.
G. Yee (1988)
10.1017/9781108628723.002
A Comparative Overview
De Waal Mj (2007)
10.1097/00007890-199707270-00010
Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients.
B. Enke (1997)
10.1136/bmj.293.6549.731
Clearance of psoriasis with low dose cyclosporin.
C. E. Griffiths (1986)
10.1046/j.1365-2133.1998.02319.x
A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
Koo (1998)
10.2165/00044011-199500101-00007
Safety Considerations with Cyclosporin and Other Systemic Therapy in the Treatment of Severe Psoriasis
U. Mrowietz (1995)
10.1097/00007890-198905000-00012
The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients.
S. Flechner (1989)
10.1016/S0009-9236(03)00168-1
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
D. Hesselink (2003)
10.1016/S0190-9622(08)81506-X
The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study.
M. Lapidoth (1994)
10.1046/j.1365-2133.1997.6101586.x
Renal biopsy findings in long‐term cyclosporin treatment of psoriasis
H. Zachariae (1997)
10.1136/ARD.2004.024463
A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
A. Fraser (2005)
10.1056/NEJM199602223340803
A reversible posterior leukoencephalopathy syndrome.
J. Hinchey (1996)
10.1046/J.0022-202X.2001.01452.X
Cyclosporin a promotes hair epithelial cell proliferation and modulates protein kinase C expression and translocation in hair epithelial cells.
T. Takahashi (2001)
Dermatite actinique chronique severe traitee par ciclosporine: 2 cas
P. Paquet (2001)
10.1067/MJD.2000.106374
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
G. Krueger (2000)
10.1023/A:1021227019915
Long-term therapy with low dose cyclosporin A in ocular Behçet's disease*
Pinar Çakar Özdal (2004)
10.1016/0190-9622(95)91393-9
Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study
U. Mrowietz (1995)
10.1016/0002-9343(84)90356-5
Side effects of systemic cyclosporine in patients not undergoing transplantation.
A. Palestine (1984)
Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine.
Edward L Lain (2004)
10.1097/00007890-199409000-00004
CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS
J. Kovarik (1994)
10.1023/A:1025693521582
Tuberculosis in renal transplant recipients: Rifampicin sparing treatment protocol
T. Vachharajani (2004)
10.1111/j.1365-2133.1990.tb02877.x
Four years of experience with cyclosporin A for psoriasis
A. Powles (1990)
10.1111/j.1468-3083.2006.01836.x
A novel treatment for recalcitrant benign familial pemphigus
N. Usmani (2007)
10.1016/S0169-409X(02)00066-2
Genetic contribution to variable human CYP3A-mediated metabolism.
J. Lamba (2002)
Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy.
A. Ozawa (1999)
10.1007/BF01973261
Biological effects of cyclosporin A: A new antilymphocytic agent
J. Borel (1994)
10.2340/00015555-0207
Systemic treatment of severe atopic eczema: a systematic review.
J. Schmitt (2007)
10.1902/JOP.2005.76.1.3
Gingival overgrowth in children: epidemiology, pathogenesis, and complications. A literature review.
A. Doufexi (2005)
Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
S. M. Behnam (2005)
10.1111/j.1365-2133.2006.07343.x
Update on the use of ciclosporin in immune‐mediated dermatoses
C. Griffiths (2006)
10.1056/NEJM197909063011016
Cyclosporin A for psoriasis.
W. Müller (1979)
10.1161/01.HYP.26.3.436
Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients.
J. Sennesael (1995)
10.1111/j.1365-2230.1995.tb01290.x
Benign familial chronic pemphigus (Hailey‐Hailey disease) responds to cyclosporin
J. Berth-Jones (1995)
Chronic actinic dermatitis treated with cyclosporine-A.
G. Stinco (2002)
10.1097/00007890-198701000-00009
HEPATOBILIARY AND PANCREATIC COMPLICATIONS OF CYCLOSPORINE THERAPY IN 466 RENAL TRANSPLANT RECIPIENTS
M. Lorber (1987)
[Extended cyclosporine-A--treatment for severe chronic urticaria].
A. Kessel (2006)
10.1016/j.jaad.2009.03.027
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
A. Menter (2009)
10.2340/0001555576371376
Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema.
H. Granlund (1996)
10.1016/0002-9343(92)90169-C
Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis.
R. Altman (1992)
Cyclosporin-responsive hidradenitis suppurativa.
D. Buckley (1995)
10.1046/j.1365-2133.2001.03960.x
The Infants’ Dermatitis Quality of Life Index
M. Lewis-Jones (2001)
10.1111/j.1365-2133.1996.tb00705.x
Treatment of severe atopic dermatitis in childhood with cyclosporin
I. Zaki (1996)
10.1097/01.tp.0000109260.00094.01
Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A
T. Giese (2004)
10.1007/s00296-006-0168-6
Cyclosporine A as treatment of esophageal involvement in dermatomyositis
S. Mii (2006)
10.1046/j.1468-3083.2001.00129-3.x
Treatment of plantar erosive lichen planus with topical cyclosporin
M. Paçô (2001)
10.1016/S0190-9622(99)70361-0
Acitretin combination therapy.
H. Roenigk (1999)
Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.
T. Kotani (2008)
10.1046/j.1365-2230.2001.00870.x
Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis
M. Ameen (2001)
10.1001/ARCHDERM.1995.01690190043008
Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy.
C. Ellis (1995)
10.1111/j.1365-2133.1993.tb15154.x
Can cyclosporin A induce permanent remission of atopic dermatitis?
N. Sepp (1993)
10.1177/0091270003253617
The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients
C. Yates (2003)
10.1097/01.tp.0000188688.15639.03
Does Bioequivalence Between Modified Cyclosporine Formulations Translate into Equal Outcomes?
D. Taber (2005)
10.1067/MJD.2001.112400
Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
V. Ho (2001)
10.1016/J.JAAD.2005.03.005
Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine.
Mariana Abraham Phillips (2005)
10.1001/JAMA.289.19.2560
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
A. Chobanian (2003)
10.1016/J.JAAD.2004.10.006
Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.
J. Reichrath (2005)
Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed.
T. Stewart (1997)
10.1097/MPH.0B013E318030AC3B
Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graft-versus-host disease prophylaxis.
R. Somech (2007)
10.1046/J.1365-2133.2001.04063.X
Polymorphic light eruption treated with cyclosporin
D. Shipley (2001)
10.1097/01.TP.0000066352.86763.D0
Cyclosporine excretion into breast milk.
M. Moretti (2003)
10.1046/j.1365-2230.2002.00998.x
Adverse effects with long‐term cyclosporin for severe psoriasis
T. Markham (2002)
10.1016/S0190-9622(94)70271-3
Treatment of classic pityriasis rubra pilaris.
C. Dicken (1994)
10.1097/00007890-199305000-00006
THE ADVERSE IMPACT OF HIGH CYCLOSPORINE: CLEARANCE RATES ON THE INCIDENCES OF ACUTE REJECTION AND GRAFT LOSS
A. Lindholm (1993)
10.4321/S0365-66912004001200005
Enfermedad de Behçet ocular: Estudio retrospectivo
Rm Torres (2004)
10.1016/j.clpt.2004.01.009
CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation
D. Anglicheau (2004)
10.1001/ARCHDERM.136.7.868
Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.
D. Ioannides (2000)
10.1111/J.1365-2133.1991.TB14783.X
Clearing of Pyoderma gangrenosum by intralesional cyclosporin A
U. Mrowieiz (1991)
10.1111/j.1365-2230.2009.03209.x
Periungual lesions in pyoderma gangrenosum
A. Reich (2009)
10.3109/10408368709105886
Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring.
W. Vine (1987)
10.1016/j.transproceed.2008.10.085
Cyclosporine promotes epstein-barr virus-infected human B-cell transformation assayed by three correlated assay methods.
C. Chen (2009)
10.1097/00007691-200410000-00010
CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1
D. Min (2004)
10.2310/6620.2007.06025
Cyclosporin A Treatment Is Associated with Increased Serum Immunoglobulin E Levels in a Subgroup of Atopic Dermatitis Patients
D. Hijnen (2007)
10.1016/S0140-6736(84)91556-3
ASSOCIATION BETWEEN CYCLOSPORIN NEUROTOXICITY AND HYPOMAGNESAEMIA
C. Thompson (1984)
10.1056/NEJM199008023230502
Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis.
D. Eisen (1990)
10.1111/j.1365-2133.1990.tb06295.x
Analysis of side‐effects of medium‐ and low‐dose cyclosporin maintenance therapy in psoriasis
M. Rie (1990)
10.1111/j.1365-2230.2005.01983.x
Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin
R. Rose (2006)
10.1097/00007890-199502270-00005
Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients.
V. Armenti (1995)
10.1016/0190-9622(90)70009-7
Treatment of severe lichen planus with cyclosporine.
V. Ho (1990)
10.1038/17401
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Minoru Hojo (1999)
10.1016/S0002-9394(14)72077-X
Pseudotumor cerebri associated with cyclosporine use.
O. Cruz (1996)
10.1016/S0190-9622(96)90281-9
Cyclosporine in severe childhood atopic dermatitis: a multicenter study.
J. Berth-Jones (1996)
10.1111/j.1365-2133.1994.tb02936.x
Maintenance treatment with cyclosporin in atopic eczema
C. Munro (1994)
10.1016/S0733-8635(05)70234-5
Cyclosporine and tacrolimus in dermatology.
J. Cather (2001)
10.1016/S0190-9622(94)70138-5
A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study.
R. M. Grossman (1994)
Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia.
C. Fozza (2005)
Cyclosporine-induced fetotoxicity in the rat.
R. Mason (1985)
10.1016/j.clpt.2003.09.012
Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance
C. Marzolini (2004)
10.1111/j.1365-2133.1994.tb02935.x
Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis
C. Laburte (1994)
Dosage of Cyclosporin A in children with renal transplants.
P. Høyer (1984)
10.1111/j.1468-3083.2005.01259.x
Alopecia areata in Down syndrome: a clinical evaluation
C. Schepis (2005)
10.1046/j.1365-2133.2003.05394.x
Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin
T. Wetzig (2003)
10.1159/000018091
Cyclosporin in Atopic Dermatitis
J. Naeyaert (1999)
10.1007/BF00431054
Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A
A. Gupta (2004)
10.1111/j.0366-077X.2004.05949.x
Ciclosporin in psoriasis clinical practice: an international consensus statement
C. Griffiths (2004)
10.1093/AJHP/55.15.1598
Effect of obesity on cyclosporine trough concentrations in psoriasis patients.
N. Shibata (1998)
10.1007/s00415-009-0137-6
Cyclosporine-induced parkinsonism
Marco A. Lima (2009)
10.1111/j.1365-2230.1994.tb01167.x
Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use
A. Finlay (1994)
Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation.
M. Di Gioacchino (2003)
10.1067/MJD.2001.113693
Emerging treatment for epidermolysis bullosa acquisita.
L. Engineer (2001)
10.1016/S0140-6736(87)92829-7
TOPICAL CYCLOSPORIN AND PSORIASIS
C. Griffiths (1987)
10.1021/JM980307X
Immunophilins: beyond immunosuppression.
G. Hamilton (1998)
10.1111/j.0007-0963.2004.05739.x
Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities
P. Balasubramaniam (2004)
Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations.
T. Schroeder (1995)
10.1016/S0140-6736(94)90115-5
Resolution of cyclosporin-induced gingival hypertrophy with metronidazole
W. Wong (1994)
10.1016/S0140-6736(88)91335-9
INTRALESIONAL INJECTION OF CYCLOSPORIN IN PSORIASIS
A. Powles (1988)
10.1159/000018183
Cryotherapy as a Precipitant Factor in Focal and Segmental Dystonia
R. Strumia (1999)
10.1046/j.1365-2133.2002.04836.x
Cyclosporin trough levels: is monitoring necessary during short‐term treatment in psoriasis? A systematic review and clinical data on trough levels
V. M. Heydendael (2002)
10.1001/ARCHDERM.1996.03890300039008
Long-term safety of cyclosporine in the treatment of psoriasis.
R. M. Grossman (1996)
10.1111/j.1365-2133.1990.tb02886.x
Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis
G. Feutren (1990)
10.1038/clpt.1986.204
Age‐dependent cyclosporine: Pharmacokinetics in marrow transplant recipients
G. Yee (1986)
10.1002/j.1552-4604.1995.tb04131.x
Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis
Cheryl A. Elder (1995)
10.1016/S0190-9622(99)70112-X
Psoriasis causes as much disability as other major medical diseases.
S. Rapp (1999)
10.1159/000018184
Partial Response of Severe Alopecia areata to Cyclosporine A
J. Ferrando (1999)
10.1093/AJH/4.5.468
Mechanism of cyclosporine-induced hypertension.
R. Luke (1991)
10.1016/0190-9622(92)70213-Y
Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease.
M. Stiller (1992)
10.1016/0190-9622(91)70247-Y
Hypertriglyceridemia in patients with psoriasis treated with cyclosporine.
R. M. Grossman (1991)
10.1016/S0190-9622(08)81050-X
Isotretinoin treatment of severe acne in posttransplant patients taking cyclosporine.
C. Bunker (1990)
10.1023/A:1012190620854
Differences in Lipoprotein Lipid Concentration and Composition Modify the Plasma Distribution of Cyclosporine
K. Wasan (2004)
10.1016/S0272-6386(87)80045-8
The effect of ethanol on serum cyclosporine A levels in renal transplant recipients.
M. D. Paul (1987)
10.1111/j.1468-3083.2009.03389.x
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
D. Pathirana (2009)
10.1111/j.1365-4632.2007.03134.x
Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis
Y. Umezawa (2007)
10.1007/978-3-662-39946-0_228
The influence of HLA matching in cardiac allograft recipients receiving cyclosporine and azathioprine.
M. Yacoub (1987)
10.1046/J.1365-2230.2001.00881.X
Graham Little–Piccardi–Lassueur syndrome: effective treatment with cyclosporin A
L. Bianchi (2001)
10.2340/00015555-0578
Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis.
S. Fukamachi (2009)
10.1016/S0140-6736(78)91970-0
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
R. Calne (1978)
10.2340/00015555-0395
Erosive lichen planus: two uncommon cases.
C. Schepis (2008)
10.1001/ARCHDERM.134.12.1521
Treatment of lichen planus. An evidence-based medicine analysis of efficacy.
B. Cribier (1998)



This paper is referenced by
10.1111/j.1365-3164.2011.00983.x
Adverse events in 50 cats with allergic dermatitis receiving ciclosporin.
Nicole A Heinrich (2011)
10.1111/PDE.12592
Oral Cyclosporine Weekend Therapy: A New Maintenance Therapeutic Option in Patients with Severe Atopic Dermatitis
C. G. Colmenero (2015)
10.5021/ad.2017.29.5.608
Therapeutic Efficacy of Combination Therapy Using Oral Cyclosporine with a Dietary Supplement (Pantogar®) in Twenty-Nail Dystrophy
S. Oh (2017)
10.1016/j.bbrep.2016.08.021
Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis mice
Kodai Saitoh (2016)
10.1016/S0716-8640(11)70489-8
Psoriasis y nuevas terapias
N. R. E. Chouela (2011)
10.1007/s10067-019-04469-6
Low-dose cyclosporine for active lupus nephritis: a dose titration approach
Kittiwan Sumethkul (2019)
10.1016/j.jaad.2014.09.008
Cutaneous pseudolymphoma: a rare side effect of cyclosporine.
C. Foley (2015)
10.1016/j.jaad.2013.12.013
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease.
Mary E Horner (2014)
10.1111/ajd.12392
A clinical audit of high‐cost and off‐label drug use in dermatology
N. Ong (2017)
10.1111/jdv.15709
European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period
C. Vestergaard (2019)
10.1007/s40257-016-0213-5
Current and Emerging Therapies for Itch Management in Psoriasis
C. Stull (2016)
10.1097/DSS.0000000000001190
Efficacy of Cyclosporine After Autologous Noncultured Melanocyte Transplantation in Localized Stable Vitiligo—A Pilot, Open Label, Comparative Study
Sharad Mutalik (2017)
10.1016/J.PIEL.2016.03.006
Efectos adversos de los fármacos inmunosupresores de uso común en dermatología
Verónica Vial Letelier (2016)
10.1002/cbic.201200621
Fine Tuning the Inhibition Profile of Cyclosporine A by Derivatization of the MeBmt Residue
E. Prell (2013)
10.1186/s13052-016-0229-8
Consensus Conference on Clinical Management of pediatric Atopic Dermatitis
E. Galli (2016)
10.1111/jdv.14066
Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients
Á. Hernández-Martín (2017)
10.1007/s00405-017-4786-2
Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis
E. Senturk (2017)
10.1111/ajd.12526
Monitoring recommendations for oral azathioprine, methotrexate and cyclosporin in a paediatric dermatology clinic and literature review
J. Yee (2018)
New Oral Therapies for Psoriasis: A Comprehensive Review.
G. Goldenberg (2016)
10.1016/B978-0-323-35868-2.00074-8
Chapter 74 – Urticaria
Apple A. Bodemer (2018)
10.1016/J.JAAD.2020.02.044
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
A. Menter (2020)
Moderate and Severe Psoriasis Vulgaris: therapy options(conventional therapies)
M. Martínez (2013)
10.1111/j.1600-0765.2011.01412.x
Molecular events associated with ciclosporin A-induced gingival overgrowth are attenuated by Smad7 overexpression in fibroblasts.
L. M. Sobral (2012)
10.5227/SKINCANCER.26.316
A case of S^|^eacute;zary syndrome diagnosed after the administration of cyclosporin
Yohei Iwata (2011)
10.1007/s15014-015-0464-2
Systemische immunsuppressive Therapie in der Kinderdermatologie
Antonia Reimer (2015)
10.4172/PROA.1000103
Cardiovascular and Metabolic Comorbidities of Psoriasis
Ayman Elgendy (2016)
10.1007/978-3-662-45840-2_6
Targeted Therapies and Biomarkers for Personalized Treatment of Psoriasis
F. Villanova (2015)
10.1016/j.det.2014.09.008
Current and future oral systemic therapies for psoriasis.
J. Kelly (2015)
10.1016/j.det.2014.09.004
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
C. Ryan (2015)
10.1111/j.1529-8019.2012.01491.x
Management of cutaneous dermatomyositis
Christina Lam (2012)
Management of psoriasis vulgaris
Abdul Majid Hazreen (2013)
Application of lipid nanoparticles for the delivery of methotrexate for dermal treatment of psoriasis
M. Pinto (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar